Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DENNER ALEXANDER J | Director | Mar 10 | Buy | 10.54 | 75,000 | 790,500 | 16,390,000 | Mar 10 07:06 PM | DENNER ALEXANDER J | Director | Mar 08 | Buy | 10.30 | 150,000 | 1,545,000 | 16,315,000 | Mar 10 07:06 PM | DENNER ALEXANDER J | Director | Mar 05 | Buy | 10.01 | 175,000 | 1,751,750 | 16,165,000 | Mar 05 07:19 PM | DENNER ALEXANDER J | Director | Mar 04 | Buy | 10.00 | 250,000 | 2,500,000 | 15,990,000 | Mar 05 07:19 PM | DENNER ALEXANDER J | Director | Mar 03 | Buy | 10.02 | 350,000 | 3,507,000 | 15,740,000 | Mar 05 07:19 PM | DENNER ALEXANDER J | Director | Mar 02 | Buy | 9.56 | 500,000 | 4,780,000 | 15,390,000 | Mar 02 08:18 PM | DENNER ALEXANDER J | Director | Mar 01 | Buy | 9.60 | 344,900 | 3,311,040 | 14,890,000 | Mar 02 08:18 PM | DENNER ALEXANDER J | Director | Feb 26 | Buy | 9.20 | 505,100 | 4,646,920 | 14,545,100 | Mar 02 08:18 PM | Owens Edward P | Director | Feb 26 | Buy | 8.90 | 3,000 | 26,700 | 218,954 | Mar 02 04:41 PM | MCCOURT Thomas A | President | Feb 26 | Sale | 9.11 | 14,685 | 133,780 | 471,577 | Mar 02 04:40 PM | Mallon Mark | Chief Executive Officer | Feb 26 | Sale | 9.11 | 30,675 | 279,449 | 470,605 | Mar 02 04:37 PM | Kilroy Conor | SVP, GC & Secretary | Feb 26 | Sale | 9.11 | 6,989 | 63,670 | 122,336 | Mar 02 04:36 PM | Consylman Gina | SVP, CFO & Treasurer | Feb 26 | Sale | 9.11 | 18,406 | 167,679 | 336,244 | Mar 02 04:34 PM | Shetzline Michael | CMO, SVP & Head of Drug Devt. | Feb 26 | Sale | 9.11 | 4,439 | 40,439 | 160,859 | Mar 02 04:44 PM | Rickard Jason | SVP, Chief Operating Officer | Feb 26 | Sale | 9.11 | 13,651 | 124,361 | 306,682 | Mar 02 04:43 PM | Owens Edward P | Director | Feb 25 | Buy | 9.11 | 5,000 | 45,550 | 215,954 | Feb 26 05:15 PM | Owens Edward P | Director | Feb 24 | Buy | 9.26 | 7,000 | 64,820 | 210,954 | Feb 26 05:15 PM | MCCOURT Thomas A | President | Dec 14 | Option Exercise | 9.89 | 99,988 | 988,881 | 421,720 | Dec 16 04:49 PM | MacDonald Kelly | Chief Accounting Officer | Dec 04 | Option Exercise | 9.12 | 5,639 | 51,428 | 98,680 | Dec 08 04:01 PM | MacDonald Kelly | Chief Accounting Officer | Dec 04 | Sale | 12.50 | 5,639 | 70,488 | 93,041 | Dec 08 04:01 PM | MacDonald Kelly | Chief Accounting Officer | Nov 11 | Option Exercise | 9.31 | 3,561 | 33,153 | 96,602 | Nov 13 04:02 PM | MacDonald Kelly | Chief Accounting Officer | Nov 11 | Sale | 11.75 | 3,561 | 41,842 | 93,041 | Nov 13 04:02 PM | Kilroy Conor | SVP, GC & Secretary | Nov 09 | Sale | 10.92 | 836 | 9,129 | 128,833 | Nov 10 04:09 PM | Consylman Gina | SVP, CFO & Treasurer | Nov 09 | Sale | 10.92 | 1,415 | 15,452 | 269,699 | Nov 10 04:03 PM | Rickard Jason | SVP, Chief Operating Officer | Nov 09 | Sale | 10.92 | 394 | 4,302 | 235,382 | Nov 10 04:12 PM | MacDonald Kelly | Chief Accounting Officer | Nov 09 | Sale | 10.92 | 925 | 10,101 | 93,041 | Nov 10 04:10 PM | MacDonald Kelly | Chief Accounting Officer | Nov 06 | Sale | 11.25 | 1,872 | 21,060 | 93,966 | Nov 10 04:10 PM | MacDonald Kelly | Chief Accounting Officer | Oct 08 | Sale | 10.50 | 22,714 | 238,497 | 95,838 | Oct 13 04:03 PM | McHugh Julie | Director | Sep 08 | Sale | 9.77 | 7,950 | 77,672 | 123,107 | Sep 09 06:26 PM | Rickard Jason | SVP, Chief Operating Officer | Aug 17 | Sale | 10.14 | 689 | 6,986 | 235,776 | Aug 19 04:05 PM | MacDonald Kelly | Chief Accounting Officer | Aug 17 | Sale | 10.14 | 575 | 5,830 | 118,552 | Aug 19 04:01 PM | OLANOFF LAWRENCE S | Director | Jun 10 | Sale | 10.06 | 11,350 | 114,181 | 68,629 | Jun 12 04:32 PM | Rickard Jason | SVP, Chief Operating Officer | May 11 | Sale | 10.35 | 510 | 5,278 | 234,580 | May 13 05:23 PM | MCCOURT Thomas A | President | May 11 | Sale | 10.35 | 1,697 | 17,564 | 319,847 | May 13 05:22 PM | MacDonald Kelly | Chief Accounting Officer | May 11 | Sale | 10.35 | 1,153 | 11,934 | 118,147 | May 13 05:20 PM | Mallon Mark | Chief Executive Officer | May 11 | Sale | 10.35 | 23,206 | 240,182 | 501,280 | May 13 05:21 PM | Kilroy Conor | SVP, GC & Secretary | May 11 | Sale | 10.35 | 716 | 7,411 | 128,921 | May 13 05:19 PM |
|